Study guide

6.1 Diabetes Mellitus & Metabolic Complications

MRCPI in General Medicine Part I Written

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Strategy & Foundation

1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy

2 Chapter 2: Cardiology & Vascular Medicine

2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases

3 Chapter 3: Respiratory Medicine

3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea

4 Chapter 4: Gastroenterology & Hepatology

4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition

5 Chapter 5: Nephrology & Acid-Base Disorders

5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders

6 Chapter 6: Endocrinology & Diabetes

6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes

7 Chapter 7: Rheumatology & Clinical Immunology

7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology

8 Chapter 8: Haematology & Medical Oncology

8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies

9 Chapter 9: Neurology & Dermatology

9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease

10 Chapter 10: Acute Medicine, Critical Care & Geriatrics

10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care

11 Chapter 11: Clinical Pharmacology & Therapeutics

11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety

12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics

12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics

6.1 Diabetes Mellitus & Metabolic Complications

Key Takeaways Explain This Topic AI

Diabetes mellitus is diagnosed by an HbA1c ≥ 48 mmol/mol (6.5%), fasting plasma glucose ≥ 7.0 mmol/L, or 2-hour post-OGTT glucose ≥ 11.1 mmol/L in symptomatic patients.

Diabetic Ketoacidosis (DKA) requires the triad of blood glucose > 11.0 mmol/L (or known DM), venous pH < 7.30 or HCO3⁻ < 15.0 mmol/L, and blood ketones ≥ 3.0 mmol/L; managed with fixed-rate IV insulin (0.1 units/kg/h) and 0.9% NaCl.

Hyperosmolar Hyperglycemic State (HHS) is characterized by glucose > 30.0 mmol/L, serum osmolality > 320 mOsm/kg, and minimal ketosis; management prioritizes cautious 0.9% NaCl fluid replacement to lower osmolality by 3–5 mOsm/kg/h.

Metformin requires dose reduction at eGFR < 45 mL/min/1.73m² and cessation at eGFR < 30 mL/min/1.73m², whereas SGLT2 inhibitors retain cardiorenal benefits down to an eGFR of 20 mL/min/1.73m².

Last updated: July 2026

  • 6.1 Diabetes Mellitus & Metabolic Complications
  • Diagnostic Criteria & Classification

The diagnosis of diabetes mellitus (DM) relies on standardized biochemical thresholds established by international guidelines. In a symptomatic individual (polyuria, polydipsia, unexplained weight loss), a single abnormal laboratory value is diagnostic; in asymptomatic individuals, two abnormal tests (either from the same sample or on separate days) are required.

  • Diagnostic Criteria Summary
  • HbA1c : ≥ 48 mmol/mol (6.5%)
  • Fasting Plasma Glucose (FPG) : ≥ 7.0 mmol/L (126 mg/dL) after an 8-hour fast
  • 2-Hour Post-OGTT Glucose : ≥ 11.1 mmol/L (200 mg/dL) following a 75 g oral glucose load
  • Random Plasma Glucose : ≥ 11.1 mmol/L in the presence of classic hyperosmolar or glycemic symptoms
  • Differentiating Type 1 vs. Type 2 Diabetes

Differentiating Type 1 DM (T1DM) from Type 2 DM (T2DM) and atypical forms such as Latent Autoimmune Diabetes in Adults (LADA) or Maturity-Onset Diabetes of the Young (MODY) is essential for selecting appropriate therapy. Pancreatic autoantibodies—specifically glutamic acid decarboxylase (anti-GAD65) , islet antigen-2 (IA-2) , and zinc transporter 8 (ZnT8) —are positive in > 90% of newly diagnosed T1DM patients. Fasting or stimulated serum C-peptide provides an index of endogenous insulin secretion; levels < 200 pmol/L confirm absolute insulin deficiency, whereas levels > 600 pmol/L favor T2DM or insulin resistance.

Pharmacological Management of Type 2 Diabetes

Modern management guidelines prioritize organ protection—specifically reducing major adverse cardiovascular events (MACE), heart failure hospitalizations, and chronic kidney disease (CKD) progression—over simple HbA1c lowering.

First-Line & Cardiorenal Protective Agents

Metformin (Biguanide) : Decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity. It is weight-neutral and does not cause hypoglycemia. Common side effects include gastrointestinal distress and Vitamin B12 deficiency. Renal Dosing : Reduce dose by 50% when eGFR is 30–45 mL/min/1.73m²; stop immediately if eGFR drops < 30 mL/min/1.73m² due to the risk of lactic acidosis.

SGLT2 Inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin) : Inhibit sodium-glucose cotransporter 2 in the proximal renal tubule, promoting glucosuria. Mandatory in T2DM with established atherosclerotic cardiovascular disease (ASCVD), heart failure (HFrEF/HFpEF), or diabetic nephropathy (urine ACR > 3 mg/mmol). Benefits persist down to an eGFR of 20 mL/min/1.73m². Exam Pearls : Risks include mycotic genital infections, volume depletion, and euglycemic DKA (blood glucose < 14 mmol/L with severe ketoacidosis).

GLP-1 Receptor Agonists (Semaglutide, Liraglutide, Dulaglutide) : Incretin mimetics that enhance glucose-dependent insulin secretion, suppress glucagon release, and delay gastric emptying. Indicated for T2DM with high ASCVD risk or obesity. Contraindications : Personal or family history of medullary thyroid carcinoma or MEN 2.

DPP-4 Inhibitors (Sitagliptin, Linagliptin) : Prevent degradation of endogenous GLP-1. Weight-neutral with minimal hypoglycemia risk. Note: Do NOT combine DPP-4 inhibitors with GLP-1 receptor agonists.

Sulfonylureas (Gliclazide, Glimepiride) : Stimulate pancreatic beta-cell insulin secretion via ATP-sensitive K+ channel closure. Associated with weight gain and high hypoglycemia risk.

Acute Metabolic Crises: DKA vs. HHS

Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS) represent life-threatening emergencies requiring prompt recognition and structured protocol-driven therapy.

  • Clinical Parameter Diabetic Ketoacidosis (DKA) Hyperosmolar Hyperglycemic State (HHS)
  • Primary Population Type 1 DM (predominantly young) Type 2 DM (elderly, frail, comorbid)
  • Onset Timeline Rapid (< 24–48 hours) Insidious (days to weeks)
  • Blood Glucose > 11.0 mmol/L (or known DM) > 30.0 mmol/L
  • Venous pH < 7.30 (severe if < 7.00) > 7.30
  • Serum Bicarbonate < 15.0 mmol/L (severe if < 10.0) > 15.0 mmol/L
  • Blood Ketones ≥ 3.0 mmol/L (urine ++ or higher) < 1.5 mmol/L
  • Serum Osmolality Variable (< 320 mOsm/kg) > 320 mOsm/kg

Primary Treatment Fixed-Rate IV Insulin (0.1 u/kg/h) + IV 0.9% NaCl Cautious IV 0.9% NaCl (target ΔOsm 3–5 mOsm/kg/h)

Step-by-Step DKA Management Protocol

Fluid Resuscitation : Infuse 0.9% NaCl: 1 L over 1st hour, 1 L over 2 hours, 1 L over 2 hours, 1 L over 4 hours, and 1 L over 8 hours. When blood glucose drops below 14.0 mmol/L , add 5% or 10% IV glucose at 125 mL/h while continuing insulin to prevent hypoglycemia.

Fixed-Rate Soluble Insulin Infusion (FRIII) : Administer 0.1 units/kg/hour. Continue FRIII until blood ketones are < 0.6 mmol/L and venous pH is > 7.30. Do NOT stop insulin based solely on normalized blood glucose.

Potassium Replacement : Insulin drives potassium intracellularly.

Serum K+ < 3.5 mmol/L: Hold insulin, administer IV potassium urgently.

Serum K+ 3.5–5.5 mmol/L: Add 20–30 mmol KCl per liter of IV fluid.

Serum K+ > 5.5 mmol/L: Omit potassium, recheck hourly.

Step-by-Step HHS Management Protocol

Gradual Volume Expansion : The central deficit in HHS is extreme dehydration (often 10–22% of total body water). Infuse 0.9% NaCl over 48 hours. Target a reduction in serum osmolality of 3–5 mOsm/kg/hour . Rapid osmolality drop risks cerebral edema and central pontine myelinolysis.

Low-Dose Fixed Insulin : Initiate fixed-rate IV insulin (0.05 units/kg/hour) ONLY IF blood glucose fails to decline despite adequate 0.9% NaCl fluid replacement or if significant ketonemia is present.

Chronic Microvascular & Macrovascular Complications

Diabetic Retinopathy : Screen annually. Graded into Background (microaneurysms, dot hemorrhages), Pre-proliferative (cotton wool spots, venous beading), and Proliferative (neovascularization requiring urgent panretinal photocoagulation). Diabetic maculopathy requires anti-VEGF intravitreal injections.

Diabetic Nephropathy : Screen annually via urine albumin-to-creatinine ratio (ACR). Microalbuminuria is defined as ACR 3–30 mg/mmol; macroalbuminuria as ACR > 30 mg/mmol. Initiate ACE inhibitors or ARBs as first-line therapy regardless of baseline blood pressure, combined with SGLT2 inhibitors.

Diabetic Neuropathy : Presents as distal symmetric sensorimotor polyneuropathy ("glove-and-stocking"). Autonomic neuropathy presents with gastroparesis, postural hypotension, resting tachycardia, or neurogenic bladder. First-line treatments for painful neuropathy include Duloxetine, Pregabalin, or Amitriptyline.